US Pharma MarketingFDA approves Mirum’s drug for ultra-rare soft tissue disease
FDA approved Mirum Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals:…
The FDA has approved the third treatment for a debilitating genetic disease that turns muscle and connective tissue to bone.
Mirum Pharmaceuticals’ zilurgisertib, which blocks the ALK2 receptor, will be marketed as Atebrioz for patients ...
Source: Endpoints News